EXOZ EXOZYMES INC revenue, earnings and financials
For the quarter ended June 30, 2026, EXOZYMES INC reported revenue of n/a, net income of −$2.88M and diluted EPS of −$0.33; for the fiscal year ended December 2025 revenue was n/a.
EXOZ annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$9.72M, net income −$9.16M (margin n/a), EPS −$1.09
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$5.93M, net income −$5.86M (margin n/a), EPS −$0.89
- Fiscal year ended Dec 2023: revenue $70.1K, gross profit n/a, operating income −$1.80M, net income −$2.04M (margin -2909.1%), EPS −$0.33
EXOZ quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.88M, EPS −$0.33
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.37M, EPS −$0.28
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$2.66M, EPS −$0.32
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.29M, EPS −$0.27
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.36M, EPS −$0.28
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.86M, EPS −$0.22
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.84M, EPS −$0.24
- Quarter ended Sep 30, 2024: revenue n/a, net income −$1.66M, EPS −$0.27
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.36M, EPS −$0.22
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.01M, EPS −$0.16
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.10M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$521K, EPS −$0.08
- Quarter ended Jun 30, 2023: revenue n/a, net income −$178K, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$241K, EPS n/a
EXOZ cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$6.50M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$8.51M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.18M, share buybacks n/a
EXOZ balance sheet
- Jun 30, 2026: cash $5.65M, total assets $7.98M, total liabilities $4.33M, shareholders' equity $3.65M
- Mar 31, 2026: cash $1.44M, total assets $4.02M, total liabilities $2.49M, shareholders' equity $1.53M
- Dec 31, 2025: cash $3.04M, total assets $5.97M, total liabilities $2.57M, shareholders' equity $3.40M
- Sep 30, 2025: cash $5.10M, total assets $7.72M, total liabilities $2.34M, shareholders' equity $5.37M
- Jun 30, 2025: cash $6.99M, total assets $9.68M, total liabilities $2.44M, shareholders' equity $7.24M
- Mar 31, 2025: cash $8.51M, total assets $11.5M, total liabilities $2.64M, shareholders' equity $8.88M
- Dec 31, 2024: cash $9.72M, total assets $13.0M, total liabilities $2.61M, shareholders' equity $10.4M
- Sep 30, 2024: cash $234K, total assets $3.56M, total liabilities $7.16M, shareholders' equity −$3.60M
Is EXOZ profitable?
No. EXOZYMES INC lost $10.2M over the last four quarters.
What is EXOZ's EPS?
Diluted earnings per share over the last four quarters were −$1.20; −$0.33 in the latest quarter.